Cancer Drug Design and Discovery

Content: 
Front Matter, Page iii
Copyright, Page iv
Introduction, Pages ix-x, Stephen Neidle
Cancer Drug Design and Discovery, Pages xi-xiii, Hilary Calvert
Editor Biography, Page xv
Contributors, Pages xvii-xviii, Paola B. Arimondo, Christian Bailly, Tracy M. Bryan, Silvia Chioato, Scott B. Cohen, Ian Collins, Robert Blake Crochet, Nicola J. Curtin, William A. Denny, Erling Donnelly, Daniele Generali, Nicolas Guilbaud, Ian R. Hardcastle, Adrian L. Harris, Philip A. Harris, John A. Hartley, Rolf W. Hartmann, Qingzhong Hu, Donna M. Huryn, Federico Innocenti,  et al.
Chapter 1 - Modern Cancer Drug Discovery: Integrating Targets, Technologies, and Treatments for Personalized Medicine, Pages 3-53, Paul Workman, Ian Collins
Chapter 2 - Pharmacogenomics and Personalized Medicines in Cancer Treatment, Pages 55-90, Wei-Peng Yong, Ross Soo, Federico Innocenti
Chapter 3 - Natural Product Chemistry and Cancer Drug Discovery, Pages 91-120, Donna M. Huryn, Peter Wipf
Chapter 4 - Structural Biology and Anticancer Drug Design, Pages 121-141, Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi, Harren Jhoti
Chapter 5 - Temozolomide: From Cytotoxic to Molecularly Targeted Agent, Pages 145-164, Malcolm F.G. Stevens
Chapter 6 - Temozolomide: Patents and the Perils of Invention, Pages 165-175, Malcolm F.G. Stevens
Chapter 7 - A New Generation of Cell-Targeted Drugs for Cancer Treatment, Pages 177-191, Paola B. Arimondo, Nicolas Guilbaud, Christian Bailly
Chapter 8 - Inhibition of DNA Repair as a Therapeutic Target, Pages 193-237, Stephany Veuger, Nicola J. Curtin
Chapter 9 - Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future, Pages 239-274, Swee Sharp, Keith Jones, Paul Workman
Chapter 10 - Inhibitors of Tumor Angiogenesis, Pages 275-317, Adrian L. Harris, Daniele Generali
Chapter 11 - The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer, Pages 319-356, Qingzhong Hu, Rolf W. Hartmann
Chapter 12 - Apoptosis in Cancer: Mechanisms, Deregulation, and Therapeutic Targeting, Pages 357-390, Zahid H. Siddik
Chapter 13 - Targeting the MDM2–p53 Protein–Protein Interaction: Design, Discovery, and Development of Novel Anticancer Agents, Pages 391-426, Ian R. Hardcastle
Chapter 14 - Targeting Altered Metabolism—Emerging Cancer Therapeutic Strategies, Pages 427-448, Minsuh Seo, Robert Blake Crochet, Yong-Hwan Lee
Chapter 15 - Inhibitors of the Phosphatidylinositol 3-Kinase Pathway, Pages 449-478, William A. Denny, Gordon W. Rewcastle
Chapter 16 - Antibody–Drug Conjugates Delivering DNA Cytotoxics, Pages 479-490, John A. Hartley
Chapter 17 - Inhibition of Telomerase: Promise, Progress, and Potential Pitfalls, Pages 491-527, Christopher G. Tomlinson, Scott B. Cohen, Tracy M. Bryan
Chapter 18 - Targeting B-RAF: The Discovery and Development of B-RAF Inhibitors, Pages 529-563, Philip A. Harris
Chapter 19 - Failure Modes in Anticancer Drug Discovery and Development, Pages 567-581, Richard A. Walgren, Christopher A. Slapak
Chapter 20 - Anticancer Drug Registration and Regulation: Current Challenges and Possible Solutions, Pages 583-607, Erling Donnelly, Silvia Chioato, David Taylor
Color Plates, Pages 1-32
Glossary, Pages 609-611
Index, Pages 613-622